May 18, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CLEVELAND — Researchers are beginning to understand the pathogenesis of dermatomyositis, leading to new, targeted therapies for the disease, according to a speaker at Cleveland Clinic’s Medical Dermatology Therapy Update IV. “Dermatomyositis is starting to have its moment,” Lisa Christopher-Stine, MD, MPH, director of Johns Hopkins Myositis Precision Medicine Center of Excellence, told
May 18, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according…

Treatment with once-daily brepocitinib improved skin disease, muscle and physical function measures for adults with…

DESTIN, Fla. — New treatments have improved outcomes in lupus, but preventing disease in the early stages remains elusive,…

Sono state pubblicate su Annals of the rheumatic diseases, una delle riviste scientifiche di maggiore rilievo nel campo della…

Researchers are testing CAR T cell therapy as a way to reset the immune system.

ORLANDO — Initiation of biologic treatment for asthma is low despite availability, and adherence is low as well despite its…